



Metacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021

June 17, 2021

SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present data at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2021, being held virtually from June 23-26, 2021. Data to be presented includes results from the Company's Phase 1 trial of MET642, a farnesoid X receptor (FXR) agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH), as well as one oral presentation and one poster focused on preclinical studies examining FXR agonists in rare adult and pediatric cholestatic liver diseases.

The full list of Metacrine and partner presentations are listed below:

Poster PO-393: MET642, an FXR Agonist with a Unique Chemotype, Demonstrates a Safe, Sustained Profile in a 14-Day Randomized Study in Healthy Subjects

Presentation Date and Time: June 23, 2021, 8:00 a.m. CEST

Poster PO-2388: FXR Controls Effector Cytokine Production and Phenotype in Biliary Atresia

Presentation Date and Time: June 23, 2021, 8:00 a.m. CEST

Oral Presentation OS-2274: Farnesoid X Receptor Agonists Block Macrophage Derived IL1b Production, Disrupt Th1/Th17 Polarization of Effector Lymphocytes, and Ameliorate Disease Progression in Murine Sclerosing Cholangitis

Presenter: Dr. Astha Malik, Research Associate, Cincinnati Children's Hospital Medical Center

Presentation Date and Time: June 25, 2021, 2:45 p.m. CEST

About Metacrine

Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. The Company's two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH. MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH. To learn more, visit www.metacrine.com.

Investor & Media Contact Steve Kunszabo Metacrine, Inc. +1 (858) 369-7892 skunszabo@metacrine.com